Mullan, Karen R <br/><br/>
The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome.  [electronic resource] 

 -  Clinical endocrinology  May 2006 
 - 519-22 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0300-0664 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2265.2006.02501.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenalectomy<br/>Adrenocorticotropic Hormone--blood<br/>Adult<br/>Drug Administration Schedule<br/>Humans<br/>Middle Aged<br/>Nelson Syndrome--blood<br/>PPAR gamma--metabolism<br/>Pituitary ACTH Hypersecretion--metabolism<br/>Rosiglitazone<br/>Statistics, Nonparametric<br/>Thiazolidinediones--therapeutic use<br/>Time Factors<br/>Treatment Failure